<DOC>
	<DOCNO>NCT02525523</DOCNO>
	<brief_summary>A Phase III , multi-centre , double-blind randomise controlled trial subject chronic antibiotic refractory pouchitis . Subjects undertake &lt; 2 week screening period provide baseline data assess eligibility . At Baseline visit ( Day 1 ) eligible subject randomise 1:1 basis either ) 240 mg alicaforsen enema b ) match placebo . Study drug administer nightly ( go bed ) include week 6 . Following Day 1 Visit , subject return clinic safety efficacy assessment Week 3 , 6 , 10 , 18 26 . Subjects may receive certain permitted medication per Entry Criteria , must remain stable dos throughout trial . Introduction new medication pouchitis , dose change exist concomitant medication pouchitis , detail protocol , permit . Clinical symptom associate pouchitis record daily patient diary card . Subjects undergo endoscopic examination pouch ( Screening , Weeks 6 10 ) . Where technically feasible , endoscopy provide least one biopsy sample histopathology . In addition endoscopic , histopathologic symptomatic assessment , Quality Life assess . Bloods routine assessment , include haematology biochemistry take . Bloods stool sample collect evaluate relevant biomarkers .</brief_summary>
	<brief_title>Randomized Study Topical Alicaforsen Enema Antibiotic Refractory Pouchitis</brief_title>
	<detailed_description />
	<mesh_term>Pouchitis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Alicaforsen</mesh_term>
	<criteria>1 . Written informed consent ; 2 . Male female subject , 18 year age undergone IPAA UC 3 . History pouchitis 4 . Overall PDAI score &gt; 7 5 . Must Chronic Antibiotic Refractory Pouchitis 1 . Lack effective contraception 2 . Women pregnant breastfeeding ; 3 . Strong analgesia NSAID use 4 . Change dose follow permitted med screen study : oral 5aminosalicylate ( 5 ASA ) , Oral steroid , , Immunosuppressant therapy . 5 . Rectal product 6 . Biological agent : Antitumour necrosis factor ( anti TNF ) therapy / vedolizumab ; permit within 8 week Screening Visit . 7 . All agent target pouchitis , include experimental agent , must discontinue least 8 week prior Screening Visit , period equivalent 5 halflives ( tÂ½ ) agent ( whichever longer ) 8 . Anal sphincter dysfunction 9 . Infections cytomegalovirus Clostridium Difficile 10 . Other GI pathology ( inc. intestinal malabsorption , pancreatic maldigestion etc ) differential diagnose 11 . Clinically significant and/or persistent illness ; investigator opinion , would exclude entry trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>